Repmann R et al.: Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res. 2003; Mar-Apr;23(2A):969-74 PMID 12820332
Jocham D et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004 Feb 21;363(9409):594-9 PMID 14987883
May M et al.: Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother. 2010 May;59(5):687-95 PMID 19876628
Doehn C et al.: Mode-of-Action, Efficacy, and Safety of a Homologous Multi-Epitope Vaccine in a Murine Model for Adjuvant Treatment of Renal Cell Carcinoma. Eur Urol. 2009 Jul;56(1):123-31 PMID 18550267
Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol 2008;181:5829–5835 PMID 18941170
Wittke S et al.: Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine. OncoTargets and Therapy 2016, 9:523-537 PMID 26889089
